Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | GLS | O94925 | 4/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL852498 | 1.00 | KDM4E (0.47) | KDM4EPKMGLSEPHX1NR1H2 | |
| SCHEMBL19511364 | 1.00 | KDM4E (0.47) | KDM4EPKMGLSEPHX1NR1H2 | |
| SCHEMBL1048156 | 0.92 | GLS (0.54) | GLSEPHX1NR1H2HPGDALDH1A1 | |
| SCHEMBL1048155 | 0.92 | GLS (0.54) | GLSEPHX1NR1H2HPGDALDH1A1 | |
| SCHEMBL30922668 | 0.92 | GLS (0.54) | GLSEPHX1NR1H2HPGDALDH1A1 | |
| SCHEMBL106242 | 0.91 | KDM4E (0.52) | KDM4EPKMGLSEPHX1NR1H2 | |
| SCHEMBL31189316 | 0.91 | NR1H2 (0.48) | KDM4EPKMGLSEPHX1NR1H2 | |
| SCHEMBL31588543 | 0.91 | NR1H2 (0.48) | KDM4EPKMGLSEPHX1NR1H2 | |
| SCHEMBL25957458 | 0.91 | NR1H2 (0.48) | KDM4EPKMGLSEPHX1NR1H2 | |
| Hydrochloric Acid SCHEMBL4219415 | 0.90 | KDM4E (0.51) | KDM4EPKMGLSEPHX1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692057-A1 | NOVEL B0AT1 INHIBITOR | Mitsubishi Tanabe Pharma Corporation (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2025-07-17 | — | — | US | disclosed |
| WO-2024210198-A1 | NOVEL B0AT1 INHIBITOR | 田辺三菱製薬株式会社 | 2024-10-10 | — | — | WO | disclosed |
| CN-117751106-A | Novel triazole-pyridine substituted pyrrolidinyl and tetrahydro-2H-pyranylacetic acid compounds as LPA antagonists | 唯久生物技术(苏州)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4330249-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | Viva Star Biosciences (Suzhou) Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232459-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) | 2022-11-03 | — | — | WO | disclosed |
| EP-3624797-A1 | KINASE INHIBITORS AND USES THEREOF | Denali Therapeutics Inc. (US) | 2020-03-25 | — | — | EP | disclosed |
| WO-2018213632-A1 | KINASE INHIBITORS AND USES THEREOF | DENALI THERAPEUTICS INC. (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001849-A1 | NOVEL B0AT1 INHIBITOR | BCAT1, BCAT2, BHMT | KDM4E 3501/4885PKM 1042/4885GLS 77/4885 |
| US-20250230140-A1 | NOVEL TRIAZOLE-PYRIDINE SUBSTITUTED PYRROLIDINYL AND TETRAHYDRO-2H-PYRANYL ACETIC ACID COMPOUNDS AS LPA ANTAGONISTS | LPAR3, LPAR2, LPAR1 | KDM4E 3096/4885PKM 1629/4885GLS 1688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.